

Transforming Local Therapies in Urology
Gil Hakim, President, IL Operations, UroGen Pharma

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

○ **Investment Rational**

Briefly describe the company's technology or therapeutic focus. The market opportunity, progress made to date key partnerships or joint ventures. Management strengths

Urogen develop the RTGel™, a sustained release formulation technology of Urological medications. \$4B are spent annually in the U.S. treating urological cancers. MitoGel™, is a novel Mitomycin formulation for the treatment of UTUC, currently in pivotal study, and BotuGel, a novel Botox formulation, licensed to Allergan for the treatment of OAB for over >\$225m. The Chairman is Dr. Arie Beldegrun.

○ **Business Strategy**

Briefly describe how the company will apply its core technology, Generate near-term and long term revenues

UroGen believes that its RTGel™ technology platform has the potential to be used in a wide range of body cavities in which increased dwell time could potentially improve therapeutic profiles of existing drugs. Beyond the goal of obtaining the first-ever approved drug for UTUC, UroGen plans to leverage this technology in additional indications to create value for patients and shareholders.

○ **Core Technology**

What is the technology, its uniqueness and its value proposition

RTGel™ is a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs and is designed to enable longer exposure to medications, making local therapy a potentially more effective treatment option. RTGel, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when heated.

○ **Product Profile/Pipeline**

Describe companies' product/pipelines, current status and market potential. Discuss milestones, potential collaboration and partnership

UroGen's lead product candidates, UGN-101 (MitoGel™, Phase 3) and URG-102 (VesiGel™, Phase 2b) are chemoablation agents designed to ablate tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including UTUC, and non-muscle low-grade bladder cancer (NMIBC), respectively. UroGen is also developing BotuGel™ (Phase 2) for overactive bladder through a partnership with Allergan PLC.

○ **What's Next?**

R&D
Preclinical / Clinicals
Organizational plans
Financial plans

Top-line data from the pivotal Phase 3 OLYMPUS study of UGN-101 is anticipated in the third quarter of 2018. Assuming positive results, UroGen plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2019. Potential approval and commercial launch of MitoGel in the US is targeted for 2H 2019.